Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients

OncoTargets and Therapy ◽

10.2147/ott.s127498 ◽

2017 ◽

Vol Volume 10 ◽

pp. 2003-2007 ◽

Author(s):

Jun Chen ◽

Hui Li ◽

Ronglin Pang ◽

Jia Huang

Keyword(s):

Lung Adenocarcinoma ◽

Programmed Death Ligand 1 ◽

Programmed Death

Download Full-text

Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma

Human Pathology ◽

10.1016/j.humpath.2020.10.014 ◽

2021 ◽

Vol 108 ◽

pp. 12-21

Author(s):

Naoki Yanagawa ◽

Satoshi Shiono ◽

Makoto Endo ◽

Shin-ya Ogata ◽

Noriyuki Yamada ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Lung Adenocarcinoma ◽

Growth Factor Receptor ◽

P53 Expression ◽

Programmed Death Ligand 1 ◽

Programmed Death ◽

Epidermal Growth ◽

Download Full-text

P2.04-01 Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.08.1225 ◽

2018 ◽

Vol 13 (10) ◽

pp. S730

Author(s):

G. Cruz-Rico ◽

X. Popa Navarro ◽

A. Avilés-Salas ◽

K.Y. Flores-Vélez ◽

A. Cardona ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Tumor Cells ◽

Histological Subtype ◽

Programmed Death Ligand 1 ◽

Programmed Death

Download Full-text

Non‐bacterial cystitis with increased expression of programmed death‐ligand 1 in the urothelium: An unusual immune‐related adverse event during treatment with pembrolizumab for lung adenocarcinoma

IJU Case Reports ◽

10.1002/iju5.12211 ◽

2020 ◽

Vol 3 (6) ◽

pp. 266-269

Author(s):

Yohei Ueki ◽

Masahiro Matsuki ◽

Terufumi Kubo ◽

Rena Morita ◽

Yoshihiko Hirohashi ◽

...

Keyword(s):

Adverse Event ◽

Lung Adenocarcinoma ◽

Programmed Death Ligand 1 ◽

Related Adverse Event ◽

Programmed Death

Download Full-text

Exosomes from Intermittent Hypoxia Treated Lung Adenocarcinoma Cell Line Up-regulate Programmed Death Ligand 1 Expression through HIF-1a Pathway in Macrophages

10.1183/13993003.congress-2020.3945 ◽

2020 ◽

Author(s):

yuanling liu ◽

Xinglin Gao ◽

Minzhen Lu ◽

Jianan Chen ◽

Siqi Li

Keyword(s):

Lung Adenocarcinoma ◽

Cell Line ◽

Intermittent Hypoxia ◽

Adenocarcinoma Cell Line ◽

Programmed Death Ligand 1 ◽

Adenocarcinoma Cell ◽

Lung Adenocarcinoma Cell Line ◽

Programmed Death

Download Full-text

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma

Translational Lung Cancer Research ◽

10.21037/tlcr-20-893 ◽

2021 ◽

Vol 10 (2) ◽

pp. 699-711

Author(s):

Minsu Kang ◽

Changhee Park ◽

Se Hyun Kim ◽

Sock Won Yoon ◽

Koung Jin Suh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Expression Level ◽

Egfr Tyrosine Kinase Inhibitor ◽

Programmed Death Ligand 1 ◽

Egfr Tyrosine Kinase ◽

Programmed Death

Download Full-text

Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy

Journal of Cancer Research and Therapeutics ◽

10.4103/jcrt.jcrt_81_19 ◽

2020 ◽

Vol 16 (4) ◽

pp. 941

Author(s):

MiguelJ Sotelo ◽

Santiago Cabezas-Camarero ◽

Alejandro Riquelme ◽

Coralia Bueno

Keyword(s):

Radiation Therapy ◽

Lung Adenocarcinoma ◽

Stereotactic Body Radiation Therapy ◽

Term Survival ◽

Programmed Death Ligand 1 ◽

Long Term Survival ◽

Stereotactic Body Radiation ◽

Programmed Death

Download Full-text

Programmed death‐ligand 1 (PD‐L1)/thyroid transcription factor‐1 double immunohistochemical staining facilitates scoring of tumor PD‐L1 expression in cytopathology specimens from lung adenocarcinoma patients

Cancer Cytopathology ◽

10.1002/cncy.22359 ◽

2020 ◽

Author(s):

Yen‐Yu Lin ◽

Li‐Ya Lin ◽

Jen‐Fan Hang ◽

Chia‐Hung Lin ◽

Hsiang‐Ling Ho ◽

...

Keyword(s):

Transcription Factor ◽

Lung Adenocarcinoma ◽

Immunohistochemical Staining ◽

Programmed Death Ligand 1 ◽

Thyroid Transcription Factor 1 ◽

Thyroid Transcription Factor ◽

Programmed Death ◽

Double Immunohistochemical Staining ◽

Transcription Factor 1

Download Full-text

Association of Programmed Death‐Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma Receiving Crizotinib

The Oncologist ◽

10.1634/theoncologist.2020-0088 ◽

2020 ◽

Vol 25 (8) ◽

pp. 702-711 ◽

Author(s):

Ching‐Yao Yang ◽

Wei‐Yu Liao ◽

Chao‐Chi Ho ◽

Kuan‐Yu Chen ◽

Tzu‐Hsiu Tsai ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Clinical Outcomes ◽

Anaplastic Lymphoma Kinase ◽

Programmed Death Ligand 1 ◽

Anaplastic Lymphoma ◽

Programmed Death

Download Full-text

P03 Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.07.042 ◽

2018 ◽

Vol 13 (9) ◽

pp. S162

Author(s):

O. Arrieta ◽

G. Cruz-Rico ◽

A. Avilés-Salas ◽

X. Popa-Navarro ◽

K.Y. Flores-Vélez ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Tumor Cells ◽

Histological Subtype ◽

Programmed Death Ligand 1 ◽

Programmed Death

Download Full-text

Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma

Lung Cancer ◽

10.1016/j.lungcan.2021.09.011 ◽

2021 ◽

Author(s):

Kazuya Takamochi ◽

Kieko Hara ◽

Takuo Hayashi ◽

Shinji Kohsaka ◽

Fumiyuki Takahashi ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Clinicopathological Features ◽

Programmed Death Ligand 1 ◽

Programmed Death

Download Full-text